SLC5A2 and diabetes mellitus: One of the major highlights of the 2021's guideline update was that sodium-glucose cotransporter-2 (SGLT-2) inhibitors or glucagon-like peptide 1 (GLP-1) agonists (if SLGT-2 is not well tolerated) be used in people with diabetes with comorbid conditions such as chronic kidney disease and heart failure, irrespective of HbA1C or metformin use.